Evidence map›Paper›PMID 40715550›Full record

ArticleInternational journal of colorectal disease2025

Cancer cachexia onset and survival outcomes in metastatic colorectal cancer: Comparative assessment of the asian working group for cachexia and the European palliative care research collaborative criteria, and utility of modified glasgow prognostic score.

Hironori Fujii, Misato Kani, Daichi Watanabe, Yuto Miura, Wakana Chikaishi, Jesse Yu Tajima, Akitaka Makiyama, Yunami Yamada, Koichi Ohata, Chiemi Hirose and 4 more

Abstract readComparative Study
In one paragraph

Article in International journal of colorectal disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Hironori FujiiDepartment of Pharmacy, Gifu University Hospital, Gifu, Japan. fujii.hironori.u5@f.gifu-u.ac.jp.
Misato KaniLaboratory of Advanced Medical Pharmacy, Gifu Pharmaceutical University, Gifu, Japan.
Daichi WatanabeDepartment of Pharmacy, Gifu University Hospital, Gifu, Japan.
Yuto MiuraLaboratory of Advanced Medical Pharmacy, Gifu Pharmaceutical University, Gifu, Japan.
Wakana ChikaishiDepartment of Surgical Oncology, Gifu University Graduate School of Medicine, Gifu, Japan.
Jesse Yu TajimaDepartment of Surgical Oncology, Gifu University Graduate School of Medicine, Gifu, Japan.
Akitaka MakiyamaCancer Center, Gifu University Hospital, Gifu, Japan.
Yunami YamadaDepartment of Pharmacy, Gifu University Hospital, Gifu, Japan.
Koichi OhataDepartment of Pharmacy, Gifu University Hospital, Gifu, Japan.
Chiemi HiroseDepartment of Pharmacy, Gifu University Hospital, Gifu, Japan.
Hirotoshi IiharaDepartment of Pharmacy, Gifu University Hospital, Gifu, Japan.
Ryo KobayashiDepartment of Pharmacy, Gifu University Hospital, Gifu, Japan.
Nobuhisa MatsuhashiDepartment of Surgical Oncology, Gifu University Graduate School of Medicine, Gifu, Japan.
Akio SuzukiDepartment of Pharmacy, Gifu University Hospital, Gifu, Japan.

Funding

Japan Society for the Promotion of Science JP 25K10065
6 · The paper itself

Abstract

objectiveCachexia substantially affects the prognosis of patients with advanced cancer. While both the Asian Working Group for Cachexia (AWGC) and European Palliative Care Research Collaborative (EPCRC) criteria are widely used for diagnosis, their comparative effectiveness in diagnostic timing and prognostic value remain understudied.

methodsThis retrospective study included patients with metastatic colorectal cancer (mCRC) who received first-line chemotherapy between 2013 and 2023. Cachexia was assessed using three distinct criteria: AWGC criteria, defined as either weight loss > 2%, or body mass index (BMI) < 21 kg/m

resultsWe enrolled 313 patients with metastatic CRC. The 1-year cumulative incidence of cachexia showed marked variation across the different diagnostic criteria. Using the AWGC criteria, the incidence rate was 69%, whereas the EPCRC criteria identified 44% of the cases. The mGPS evaluation revealed incidence rates of 73% and 39% for scores of 1 and 2, respectively. Both AWGC- and EPCRC-defined cachexia correlated with significantly shorter overall survival (AWGC: hazard ratio (HR) = 2.41, P < 0.001; EPCRC: HR = 2.02, P < 0.001). Similarly, the mGPS scores indicated a poor prognosis.

conclusionThe AWGC criteria identified a higher incidence of cachexia earlier in the disease course compared to the EPCRC criteria and showed a stronger association with overall survival. The mGPS shows promise as an alternative diagnostic tool to traditional weight-based assessments. These findings suggest new opportunities for early diagnosis of cachexia and intervention strategies in patients with mCRC.

Indexed as

CachexiaColorectal NeoplasmsPalliative CareAgedAged, 80 and overEuropeFemaleHumansMaleMiddle AgedNeoplasm MetastasisPrognosisProportional Hazards ModelsRetrospective StudiesAWGC criteriaCancer cachexiaEPCRC criteriaMetastatic colorectal cancerModified Glasgow Prognostic ScorePrognostic valueTime-dependent analysis

Identifiers

PMID40715550
PMCPMC12296788

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.